<!DOCTYPE html>
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>
<meta content="SAS 9.4" name="generator"/>
<title>SAS Output</title>
<style>
/*<![CDATA[*/
.body.c > table, .body.c > pre, .body.c div > table,
.body.c div > pre, .body.c > table, .body.c > pre,
.body.j > table, .body.j > pre, .body.j div > table,
.body.j div > pre, .body.j > table, .body.j > pre,
.body.c p.note, .body.c p.warning, .body.c p.error, .body.c p.fatal,
.body.j p.note, .body.j p.warning, .body.j p.error, .body.j p.fatal,
.body.c > table.layoutcontainer, .body.j > table.layoutcontainer { margin-left: auto; margin-right: auto }
.layoutregion.l table, .layoutregion.l pre, .layoutregion.l p.note,
.layoutregion.l p.warning, .layoutregion.l p.error, .layoutregion.l p.fatal { margin-left: 0 }
.layoutregion.c table, .layoutregion.c pre, .layoutregion.c p.note,
.layoutregion.c p.warning, .layoutregion.c p.error, .layoutregion.c p.fatal { margin-left: auto; margin-right: auto }
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r p.warning, .layoutregion.r p.error, .layoutregion.r p.fatal { margin-right: 0 }
article, aside, details, figcaption, figure, footer, header, hgroup, nav, section { display: block }
html{ font-size: 100% }
.body { margin: 1em; font-size: 13px; line-height: 1.231 }
sup { position: relative; vertical-align: baseline; bottom: 0.25em; font-size: 0.8em }
sub { position: relative; vertical-align: baseline; top: 0.25em; font-size: 0.8em }
ul, ol { margin: 1em 0; padding: 0 0 0 40px }
dd { margin: 0 0 0 40px }
nav ul, nav ol { list-style: none; list-style-image: none; margin: 0; padding: 0 }
img { border: 0; vertical-align: middle }
svg:not(:root) { overflow: hidden }
figure { margin: 0 }
table { border-collapse: collapse; border-spacing: 0 }
.layoutcontainer { border-collapse: separate; border-spacing: 0 }
p { margin-top: 0; text-align: left }
h1.heading1 { text-align: left }
h2.heading2 { text-align: left }
h3.heading3 { text-align: left }
h4.heading4 { text-align: left }
h5.heading5 { text-align: left }
h6.heading6 { text-align: left }
span { text-align: left }
table { margin-bottom: 1em }
td, th { text-align: left; padding: 3px 6px; vertical-align: top }
td[class$="fixed"], th[class$="fixed"] { white-space: pre }
section, article { padding-top: 1px; padding-bottom: 8px }
hr.pagebreak { height: 0px; border: 0; border-bottom: 1px solid #c0c0c0; margin: 1em 0 }
.stacked-value { text-align: left; display: block }
.stacked-cell > .stacked-value, td.data > td.data, th.data > td.data, th.data > th.data, td.data > th.data, th.header > th.header { border: 0 }
.stacked-cell > div.data { border-width: 0 }
.systitleandfootercontainer { white-space: nowrap; margin-bottom: 1em }
.systitleandfootercontainer > p { margin: 0 }
.systitleandfootercontainer > p > span { display: inline-block; width: 100%; white-space: normal }
.batch { display: table }
.toc { display: none }
.proc_note_group, .proc_title_group { margin-bottom: 1em }
p.proctitle { margin: 0 }
p.note, p.warning, p.error, p.fatal { display: table }
.notebanner, .warnbanner, .errorbanner, .fatalbanner,
.notecontent, .warncontent, .errorcontent, .fatalcontent { display: table-cell; padding: 0.5em }
.notebanner, .warnbanner, .errorbanner, .fatalbanner { padding-right: 0 }
.body > div > ol li { text-align: left }
.beforecaption > h4 { margin-top: 0; margin-bottom: 0 }
.c { text-align: center }
.r { text-align: right }
.l { text-align: left }
.j { text-align: justify }
.d { text-align: right }
.b { vertical-align: bottom }
.m { vertical-align: middle }
.t { vertical-align: top }
.accessiblecaption {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.aftercaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.batch > col, .batch > colgroup > col, .batch > colgroup, .batch > tr, .batch > * > tr, .batch > thead, .batch > tbody, .batch > tfoot { border: none; }
.batch {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    padding: 7px;
    }
.beforecaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.body {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    margin-left: 8px;
    margin-right: 8px;
}
.bodydate {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    text-align: right;
    vertical-align: top;
    width: 100%;
}
.bycontentfolder {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.byline {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.bylinecontainer > col, .bylinecontainer > colgroup > col, .bylinecontainer > colgroup, .bylinecontainer > tr, .bylinecontainer > * > tr, .bylinecontainer > thead, .bylinecontainer > tbody, .bylinecontainer > tfoot { border: none; }
.bylinecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.caption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.cell, .container {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.contentfolder, .contentitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.contentproclabel, .contentprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.contents {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.contentsdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.contenttitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.continued {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    width: 100%;
}
.data {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.dataemphasis {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataemphasisfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataempty {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datafixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datastrong {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.datastrongfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.date {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.document, .errorbanner, .errorcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.errorcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.extendedpage {
    background-color: #ffffff;
    border-style: solid;
    border-width: 1pt;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
    text-align: center;
}
.fatalbanner, .fatalcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.fatalcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.folderaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footer {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.frame {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.graph > col, .graph > colgroup > col, .graph > colgroup, .graph > tr, .graph > * > tr, .graph > thead, .graph > tbody, .graph > tfoot { border: none; }
.graph {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.header {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.headersandfooters, .headerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.index, .indexaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.indexitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.indexprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.indextitle, .linecontent, .list, .list10, .list2, .list3, .list4, .list5, .list6, .list7, .list8, .list9, .listitem, .listitem10, .listitem2, .listitem3, .listitem4, .listitem5, .listitem6, .listitem7, .listitem8, .listitem9, .note, .notebanner, .notecontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.notecontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.output > col, .output > colgroup > col, .output > colgroup, .output > tr, .output > * > tr, .output > thead, .output > tbody, .output > tfoot { border: none; }
.output {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.pageno {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    text-align: right;
    vertical-align: top;
}
.pages {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.pagesdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.pagesitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.pagesproclabel, .pagesprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.pagestitle, .paragraph {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.parskip {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.prepage, .proctitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.proctitlefixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooter {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooteremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooteremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooterempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowfooterstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheader {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderemphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderemphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowheaderstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.systemfooter, .systemfooter10, .systemfooter2, .systemfooter3, .systemfooter4, .systemfooter5, .systemfooter6, .systemfooter7, .systemfooter8, .systemfooter9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: bold;
}
.systemtitle, .systemtitle10, .systemtitle2, .systemtitle3, .systemtitle4, .systemtitle5, .systemtitle6, .systemtitle7, .systemtitle8, .systemtitle9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: medium;
    font-style: normal;
    font-weight: bold;
}
.systitleandfootercontainer > col, .systitleandfootercontainer > colgroup > col, .systitleandfootercontainer > colgroup, .systitleandfootercontainer > tr, .systitleandfootercontainer > * > tr, .systitleandfootercontainer > thead, .systitleandfootercontainer > tbody, .systitleandfootercontainer > tfoot { border: none; }
.systitleandfootercontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.table > col, .table > colgroup > col, .table > colgroup, .table > tr, .table > * > tr, .table > thead, .table > tbody, .table > tfoot { border: none; }
.table {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.titleandnotecontainer > col, .titleandnotecontainer > colgroup > col, .titleandnotecontainer > colgroup, .titleandnotecontainer > tr, .titleandnotecontainer > * > tr, .titleandnotecontainer > thead, .titleandnotecontainer > tbody, .titleandnotecontainer > tfoot { border: none; }
.titleandnotecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.titlesandfooters, .usertext, .warnbanner, .warncontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.warncontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
/*]]>*/
</style>
</head>
<body class="c body">
<div style="padding-bottom: 8px; padding-top: 1px">
<div id="IDX" class="systitleandfootercontainer" style="border-spacing: 1px">
<p><span class="c systemtitle">Amino acids data set 3</span> </p>
</div>
<div style="padding-bottom: 8px; padding-top: 1px">
<table class="table" style="border-spacing: 1px" aria-label="Data Set REF.AMINO_ACIDS_SORTED_3">
<caption aria-label="Data Set REF.AMINO_ACIDS_SORTED_3"></caption>
<colgroup><col/><col/><col/><col/></colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="header" scope="col">Strengths</th>
<th class="header" scope="col">Weaknesses</th>
<th class="header" scope="col">Future_Research</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="data"> &#160;</td>
<td class="data">We acknowledge some limitations. First, given the substantial heterogeneity of DKD progression, there may be subgroups for whom our signatures may not be optimal. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Additional studies to evaluate genes involved in citrate production and conversion to aconitate will shed light on our current findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Additional research using independent cohorts and targeted assays are needed to clarify these associations and shed further light on biological mechanisms underlying metabolite levels and DKD progression. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For future work, we will use independent cohorts with varying clinical risk profiles to further evaluate our findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   A future aim is to evaluate our models on clinically distinct patient populations (e.g., by albuminuria group), and develop new signatures using an expanded set of metabolites.  XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, non-targeted metabolomics by flow-injection analysis cannot distinguish between metabolites with identical sum formula and only reports relative abundance change. In future work, we will use targeted gas chromatography-mass spectrometry or liquid chromatography–tandem mass spectrometry methods to replicate these findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, our “two-stage” approach to modeling kidney disease progression via eGFR slope has the advantage of being easy to interpret and analyze since standard statistical methods can be employed. However, this approach could entail an efficiency loss when there are missing data or irregular spaced repeated measures. A future aim is to develop appropriate weighting methods for unbalanced data. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, eGFR decline may not always be linear. However, despite the linearity assumption, eGFR slope offers ease of biological interpretation, and permits application of standard statistical modeling methods. Importantly, the CRIC Study has produced notable findings with eGFR slope as a marker for kidney disease progression (39,40). Nevertheless, we aim to examine nonlinear trajectories in future work. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="data">The major strengths of this study are the large number of individuals with T2D from 5 independent cohorts as well as adjustment for an extensive set of relevant clinical covariates and multiple testing, which diminished the risk of false-positive results. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Moreover, the use of the NMR platform provided standardized measures of metabolites, allowing exploration of measures beyond routinely measured biomarkers. This method was faster, cheaper, and thereby more accessible than the more extensive MS-based metabolomics methods and could potentially be easier to adapt to a clinical setting, although it did not provide as in-depth a characterization as, for example, MS. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The use of medications agents may affect the metabolome substantially. In a recently published paper, also from the Biobanking and Biomolecular Resources Research Infrastructure consortium, significant associations between cardiometabolic agents and several of the measured metabolites were demonstrated (44). In the present study, results were adjusted for several medications commonly used in diabetes. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">We further recognize some limitations of the study. Metabolites were measured at one timepoint and therefore did not provide information regarding within-subject variation 
in metabolite levels. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In some of the original studies, information regarding albuminuria measurements and history of micro- or macroalbuminuria was very limited. Further, we were limited by a low number of cases in the CODAM study, no diabetes duration in the RS study, and only having follow-up measurements from 2 cohorts. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Information regarding diet, which may affect the measured metabolites, was not available in all cohorts and not uniformly captured. Therefore, we could not  control for diet in this study. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Information regarding other renal markers, such as vitamin D, parathyroid hormone, and calcium, was also not available. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Since the samples originate from different studies, the storage time before metabolite measurements differed. Although all samples were stored at −80°C as recommended (45), we did find consistent results across studies, regardless of the year of sampling. This finding was also demonstrated by low heterogeneity between studies, suggesting no such influence. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Further longitudinal studies are needed to clarify whether alterations in metabolite levels precede or are consequences of renal impairment and whether a biomarker panel of both amino acid and lipid measures could potentially lead to improved prediction in the development of DKD. XXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="data">The advantage is that the bioinformatic approach incorporates molecular pathway information associated with disease progression as well as biomarkers and pathway information associated with drug response, thereby decreasing the probability of false positive findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">A limitation is that the bioinformatic approach only includes molecular features and molecular pathways which have previously been annotated and does not include novel mechanisms. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The limitations of this study include the small sample size, which hampers the statistical power of this study as well as the generalizability to the broader type 2 diabetes population because the studied population was a predominantly male Caucasian population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we compared the effect of dapagliflozin with placebo in an additional analysis, we only considered metabolites which statistically significantly changed from baseline during dapagliflozin treatment for further integration analysis because the metabolomics profile could only be determined in six patients in the placebo group. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Secondly, the short follow-up precluded assessment of the effect of dapagliflozin on eGFR decline. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thirdly, the EFFECT II trial included patients with preserved kidney function, whereas tissue renal transcriptomics was performed in patients with preserved or impaired renal function participating in the ERCB study. It is possible that the effects of dapagliflozin on the metabolites are different in patients with different clinical characteristics, demographics and degrees of renal impairment. Hence, validation of our findings in larger studies with a longer duration as well as in patients with type 2 diabetes and chronic kidney disease, such as the DAPA-CKD trial, is required (36). Unfortunately, urine was not available, which could reveal a more renal specific signal. Nevertheless, our finding that metabolites related to mitochondrial function changed was in keeping with another study using urinary metabolites (25). XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The exact mechanism of how SGLT2 inhibition improves endothelial function is not fully understood but may involve improved glycaemic and metabolic control, osmotic diuresis, and changes in sodium homeostasis as a result of increased natriuresis. XXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="data">However, our study presents important strengths: we used the case‐cohort design, which retains randomization, to both evaluate associations of 2-AAA and lysine with incident T2D and CVD. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our analyses were adjusted for multiple confounders within a well-characterized trial and, as an important novelty, we used repeated measurements of these metabolites, that allowed us to assess 2-AAA and lysine changes due to the dietary intervention. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Our study presents some limitations. First, we do not have available data on glycated hemoglobin (HbA1c), which was previously reported to be a biomarker of diabetes and CVD damage, independently of fasting glucose [23]. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Moreover, we did not find an effect of MedDiet on 1 year-changes in none of the studied metabolites. It may be possible that 1 year is not enough time to observe sound changes in metabolites, and as a consequence we did neither observe an association between 1-year changes of metabolites and the subsequent risk of T2D or CVD. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Another limitation is that our results may be not generalizable because we used a Mediterranean population at high CVD risk. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, we cannot exclude the possibility of residual confounding regarding the observational associations between metabolites and cardiometabolic outcomes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Further studies are needed to clarify the effect of diet on lysine, 2-AAA and pipecolic acid levels and the potential effect modification by dietary interventions on the CVD/T2D risk associated with these metabolites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thus, new studies are needed to evaluate if lysine pathway metabolites may add value to the prediction of risk provided by HbA1c. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Consequently, these results, especially those suggesting a potential interaction between the nutritional intervention and these 2 metabolites deserve further confirmation in independent prospective cohort studies and trials [24].</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">As such, in addition to establishing glutamine metabolism as a metabolic checkpoint for cancer immunotherapy, our studies suggest fundamental insights into the nature and role of Warburg physiology. Moreover, through the application of glutamine blockade, we demonstrate the possibility of differentially modulating the metabolism of cancer cells and anti-tumor immune cells by exploiting the differential metabolic plasticity of each cell type. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="data"> &#160;</td>
<td class="data">We are aware of certain limitations to our study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, due to differences in imputation reference panels between the studies included in the GWAS for glycine, sample sizes differed between the tested variants. Therefore certain loci, in particular those only covered in UK10K and rare variants, which have been shown to influence amino acid levels (13), may not have reached significance. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Secondly, some of the studies upon which our analyses were based were enriched for healthy participants, e.g., UK Biobank (55) and INTERVAL. It has recently been suggested that selection bias could theoretically lead to a false positive genetic association between an exposure and an outcome if both the exposure and the outcome influence the likelihood of an individual participating in the study (56). As individuals are not aware of their glycine levels, any such selection would have to be indirect through other factors that affect glycine and bias participation in each of the independent studies included in the same direction. We therefore consider the extent to which collider bias could be influencing the MR results due to a healthy participant effect to be small. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, despite undertaking sensitivity analyses, we cannot exclude the possibility that our findings may be driven by vertical pleiotropic effects of the genetic instruments. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As the metabolome is comprised of thousands of metabolites connected through numerous reactions, some of which may be unknown, the distinction between horizontal and vertical pleiotropy is difficult to make in the context of metabolomics. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The 2 SNP score, comprised of loci in genes of major enzymes of glycine catabolism, is the most specific score to the glycine pathway but still shows modest associations with some metabolites of which we cannot be sure that they are metabolically linked to glycine, e.g., the unknown metabolite X-16570, and with glycine-conjugated metabolites, which may have effects independent of glycine on cardiometabolic disease risk.  XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore, we cannot fully exclude that glycine-independent mechanisms may have biased the genetically predicted association of glycine with disease risk. Moreover, as glycine is a metabolite on the intersection of many metabolic pathways, the genetic association of glycine with cardio-metabolic diseases may represent the causal effect of a metabolite to which glycine is metabolically close linked (e.g., tetrahydrofolate or serine).XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Thus, whether certain dietary factors interact with the potential BCAA-biosynthetic component of the gut microbiome pattern, thereby affecting BCAA levels, deserves further investigation. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Despite the accumulating evidence that BCAAs are related to T2D pathogenesis, whether increased BCAA levels are a cause or consequence of T2D has not been elucidated. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX LysoPC is a signaling molecule involved in atherogenic and inflammatory processes (49), of which the major function needs to be clearly elucidated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Given that food intake and relevant nutrients possibly interact with the environment and the gut microbiome, and that these interactions would be reflected in the blood metabolites, the links among dietary intake, gut microbiota and metabolic biomarkers and their associations with T2D must be further investigated. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Because the response to the specific stimulus (e.g. chemicals, nutrients, etc.) can be distinct depending on gender and ethnic group (62), separate analysis in a certain population is required to apply the identified metabolites for planning the preventive strategy as well as for pharmacological targeting to treat T2D.</td>
</tr>
<tr>
<td class="r data">8</td>
<td class="data">Strengths of the study include the use of a well-characterised clinical trial cohort, an efficiently designed case-cohort study to yield a powerful study for a range of endpoints, which were independently adjudicated according to pre-defined criteria. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Like other RCT populations, ADVANCE study participants represent a selected cohort. For instance, ADVANCE study participants were required to have a history of CVD or CVD risk factors. Therefore, our results may not be generalisable to all individuals with diabetes, although other risk factors we measured are generally associated with risk of major endpoints in the expected directions. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Amino acids were measured in pragmatically collected plasma samples in the context of a multi-national RCT and we cannot rule out the potential for differential pre-analytical sample handling or sample degradation during storage, which may have biased our results [44], although these samples were analysed at first thaw. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We also present data suggesting broadly comparable concentrations of amino acids relative to other cohorts. Another potential limitation is the analysis of samples from non-fasted participants, although in clinical practice, fasting is rarely required among individuals with type 2 diabetes. NMR spectroscopy has been used to investigate changes in amino acids 30 min after a standardised liquid meal [45] and effects sizes were generally relatively small, although the immediate postprandial state is likely to give larger effect estimates than are at play in this study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.</td>
</tr>
<tr>
<td class="r data">9</td>
<td class="data">Our study has several strengths. Multiple uncontrolled factors may contribute to heterogeneity of metabolomic profile. We included 2 sub-populations with relatively large sample sizes to partially address the inherent shortcoming of a metabolomics study. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, the coverage of metabolites in our study is broader than that in early reports. These strengths have enabled us to identify several novel pathophysiological features associated with DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Nevertheless, several weaknesses should be mentioned, as follows: (i) This is a cross-sectional study in its design. Our data can show association but not causality. (ii) Some important clinical variables such as physical activities, diet, and comorbidities were not considered in our current study. Although the inclusion of 2 independent sub-populations may partially address this concern, validation of our findings by other independent studies is warranted. (iii) We measured urinary albumin level only once. It has been known that the day-to-day variation of albuminuria level is high (2) (iv) Due to technical limitations, we are not able to separate the isomeric species including C8-OH/ C6-DC, C14-OH/C12-DC, and C18-OH/C16-DC. An early study showed that the signals of these isomers come mainly from branched-chain dicarboxyl-acylcarnitines (22). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although targeted metabolomics provides accurate metabolite identification and quantification, it can cover only a subset of the human metabolome. Non-targeted metabolomics is needed to complement our findings. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, we would highlight that participants included in a validation sub-study had “extreme phenotype” in terms of DKD phenotype. Therefore, data obtained from this sub-population should be interpreted with caution. In addition, clinical characteristics of participants and the loadings of factors are different in discovery and validation sub-populations (Tables 1 and 4, Tables S9 and S10). Hence, direct comparisons of factors derived from these 2 subpopulations are not relevant. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Therefore, the accelerated amino acid catabolism in DKD is intriguing, and the sensory signals that trigger amino acid flux and oxidation in these patients remain largely unknown. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Accumulation of acetyl-CoA-derived C2 (acetylcarnitine), as observed in our study, points to a mismatch between energy substrate flux and its utilization in DKD. However, due to the observational nature of our study, we are unable to elucidate whether the imbalance is due to accelerated flux or a reduced downstream utilization, or both. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">10</td>
<td class="data">A strength of our study is its prospective design using general population-based cohorts. Study participants were initially free of MI, and thus we analysed only incident events. All samples were handled in a similar, unbiased manner. We controlled for a variety of demographic characteristics, lifestyle factors, medication and clinical variables. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX All data were collected and verified by trained personnel (16,23, 25) to reduce measurement error. We applied stringent QC procedures to our metabolite assays, (18) and observed no sources of systematic error. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Though nested case–cohort and case–control designs are less efficient than assaying the entire cohort, (43) we still observed associations with our approach. Also, associations for the LPC 18:2 and the metabolite score were similar for KORA and AGES-REFINE despite reports of potential bias with stratified case–control designs. (43) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">A limitation of using backward stepwise selection to reduce the set of predictors is that the pruning is done in an agnostic manner. Thus, the predictors selected may not represent the most meaningful or causal metabolites, but may be markers for unmeasured or unselected metabolites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We were unable to control for dietary intake, which is associated with incident MI. (44) This may have affected our inability to identify associations with metabolites influenced by diet, for example, tryptophan. (45, 46) Additionally, the non-fasting status of the KORA S2 cohort may have introduced variability that obscured associations in this cohort. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A key point of all biomarker discovery studies is generalisability. We incorporated samples from Germany and Iceland indicating that our associations generalise across European populations.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">We suggest that future studies of MI and metabolic profiles collect detailed dietary information and use fasting samples. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we provide substantial evidence for improved baseline discrimination for future incident MI for our novel biomarkers, future studies are needed to formulate and validate an incident MI risk scoring function based on these metabolite biomarkers.</td>
</tr>
<tr>
<td class="r data">11</td>
<td class="data"> &#160;</td>
<td class="data">In such instances, assessment of changes in metabolites across the diseased organ would prove more valuable, such as sampling arterial blood and the coronary sinus for the heart (see limitations of metabolomics described in the section Metabolomics), or having a tissue biopsy to compare against the serum/plasma sample. Nonetheless, due to the ease of obtaining a serum / plasma sample versus collecting a tissue biopsy or invasive catheterization, we must rely on molecular explorations in animal models of disease to confirm and / or understand novel metabolic alterations identified from human blood-based metabolomic signatures.</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">12</td>
<td class="data"> &#160;</td>
<td class="data">The observational assessment of the effects of statins may be confounded, in particular by indication for treatment. However, the comparisons of metabolic changes over 2 time points reduced such confounding. Furthermore, the Mendelian randomization approach to proxy the metabolic effects of HMGCR inhibition is generally free of this limitation (18,40). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The rs12916-T allele in HMGCR has previously been rigorously associated with lower expression of HMGCR in the liver and lower circulating LDL-C levels (13,19), supporting the validity of this common variant as a genetic instrument. Information on statin type and dosage was generally not available; however, results were coherent across the 4 longitudinal cohorts despite large differences in demographics and follow-up time. The genetic analyses were also consistent across 8 cohorts with a wide age span. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The limited statistical power and the predominantly young study population preclude us from ruling out minor effects of statins on non-lipid biomarkers. Nonetheless, the results set upper limits for the effects of HMGCR inhibition on multiple circulating biomarkers not previously investigated. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">13</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
</tr>
<tr>
<td class="r data">14</td>
<td class="data">The strengths of this study are that we have measured a large number of biomarkers covering numerous pathophysiological pathways. We have also made use of k-fold cross-validation and machine learning methods that avoid the problem of overfitting when testing large numbers of associations and increase the generalizability of findings to other settings. XXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">There are also weaknesses. The sample size is modest and only one cohort has been studied and validation in external cohorts is needed. We used a dichotomous variable for albuminuria because no single method was used for all samples to assess albuminuria status. As a result there is potential for residual confounding because of albuminuria. However, a sensitivity analysis of the subgroup with albumin concentration data measured by a single method showed that the increment in AUROC achieved by adding biomarkers to the clinical covariates was not reduced by the use of a continuous measure of albuminuria rather than the dichotomous variable. Thus, we think it is reasonable to conclude that the biomarkers are not materially affected by residual confounding. Another weakness is that we only have limited data from blinded duplicate samples because of limited volume availability, although in general the repeatability data were good (see Supplementary Methods online). We also note that the effect of errors in measurement act to reduce the power to detect associations rather than introduce false positive associations. Third, we did not have a measure of every biomarker in every sample that required us to impute missing values. However, the degree of missng at random was not high with only 6 biomarkers in the study having ≥30% of values imputed, and a sensitivity analysis examining individual biomarker associations after adjustment for clinical covariates in the non-imputed data showed consistent associations with those seen in the imputed data set. In keeping with our aim to identify biomarkers that might improve clinical trial stratification we have restricted the study to individuals with CKD3 at baseline. It is not possible to conclude that biomarkers that are associated with progression at this stage will also be predictive of progression in individuals with CKD1 or CKD2 and studies are needed to examine biomarkers in such individuals. It should also be noted that panels of biomarkers predicting from earlier stages of renal disease are more likely to include biomarkers that are in the causal pathway, whereas panels predicting from CKD3 may include biomarkers altered secondarily because of declines in glomerular filtration. The study also does not identify</td>
<td class="data">However, further studies of the generalizability of findings are warranted. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Validation in external cohorts is needed. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is not possible to conclude that biomarkers that are associated with progression at this stage will also be predictive of progression in individuals with CKD1 or CKD2 and studies are needed to examine biomarkers in such individuals. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Identified novel associations of biomarkers that warrant further investigation for relevance to pathogenesis of kidney disease in type 2 diabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">15</td>
<td class="data">This is the first population-based study on AA profiles with a large number of South Asian migrants and native Europeans conducted in the same setting and with a lengthy follow-up. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, loss to follow-up did not differ by ethnicity, and it is unlikely that the strengths of the associations within ethnic groups would differ in those lost to follow-up. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">However, the study was conducted only in middle-aged men and the findings may not apply to women or other age groups. Loss to follow-up occurred in approximately one-third of the participants, and while the baseline characteristics of the whole study group and those with follow-up data only were almost identical, it is likely that those lost to follow-up would be more at risk of developing diabetes and have more adverse outcomes, leading to a possible underestimation of the associations between AAs and incident diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We did not have baseline measures of hepatic function; hence we could not explore hepatic effects on AA levels and associations. In addition, many associations have been compared within and between ethnic groups, and although the trends are consistent with previously published results in European populations, caution is needed in interpreting multiple comparisons. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, comparisons of AA associations with incident diabetes within and between South Asian subgroups are based on small numbers and should be interpreted with caution. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Abdominal adipose tissue in South Asian individuals contains larger and more dysfunctional adipocytes [37]. It has also been suggested that increased AA levels may result from increased protein turnover in association with increased central obesity and reduced lean body mass [7]; this is a plausible, but untested, explanation for the increased levels of isoleucine, tyrosine, alanine and glutamine seen in our more centrally obese South Asian men. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further research is needed to understand the role of diet in the relationship between serum AA levels and risk of diabetes XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">16</td>
<td class="data">This popn =&gt; high burden of cardiovascular risk factors, BUT =&gt; detailed angiographic phenotype is a definite strength. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This is the largest study to date of metabolic profiling in CAD. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The use of high-throughput molecular technology =&gt; a quantitative, targeted metabolic platform =&gt; allowed us to identify metabolic signatures that independently discriminate extremes of CAD severity and validate our results from exploratory analyses in smaller sample sets. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The Findings could help in understanding the mechanisms of CAD development.</td>
<td class="data">Study population =&gt; convenience sample (Convenience sampling (also known as grab sampling, accidental sampling, or opportunity sampling) is a type of non-probability sampling that involves the sample being drawn from that part of the population that is close to hand. This type of sampling is most useful for pilot testing.) of individuals referred for cardiac catheterization for concern of CAD. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Did not account for dietary + environmental variations in metabolite levels, BUT all samples were collected from patient in a fasting state + all metabolite profiling was done in a single batch =&gt; to avoid batch effect confounders. No adjustment for medication use or lipids in our analyses, as similar adjustments in our previous work showed minimal influence on associations of factors with CAD (3).</td>
<td class="data">More studies are needed to elucidate the underlying biologic pathways that mediate the association of BCAAs with CAD severity.</td>
</tr>
<tr>
<td class="r data">17</td>
<td class="data">Glutamine is a versatile nutrient required for the survival and growth of a potentially large subset of tumors. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data"> &#160;</td>
<td class="data">Work over the next several years should produce a more accurate picture of the molecular determinants of glutamine addiction and the identification of death pathways that execute cells when glutamine catabolism is impaired. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Advancement of glutamine-based imaging into clinical practice should soon make it possible to differentiate tumors that take up glutamine from those that do not. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, the development of safe, high-potency inhibitors of key metabolic nodes should facilitate therapeutic regimens featuring inhibition of glutamine metabolism.</td>
</tr>
<tr>
<td class="r data">18</td>
<td class="data"> &#160;</td>
<td class="data"> &#160;</td>
<td class="data">Although we have no explanation for this novel observation, and cannot rule out that the relatively small sample size may have brought about this finding, it may be of importance for further studies on the role of BCAAs in the regulation of insulin sensitivity, particularly in the aspect of NAFL. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Whether these effects and putatively beneficial effects of lyso-PC C16:0 on glucose uptake in other tissues translate into a positive effect on whole-body glucose uptake needs to be investigated in future studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In support of this hypothesis,we found lyso-PC C16:0 to be negatively associated with insulin resistance in subjects with high, but not low, liver tissue lipid content. Certainly, because of the very small sample size of this group, we cannot draw definite conclusions from this observation. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In conclusion, in the future, a metabolomic fingerprint, most robust in the class of lyso-PCs, may be able to differentiate insulin-sensitive from insulin-resistant subjects with NAFL. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Furthermore, as low lyso-PC levels appear to specifically be a marker of NAFL-associated insulin resistance, these findings may highlight novel and interesting pathways for the studies on the pathogenesis of insulin resistance in NAFL.</td>
</tr>
<tr>
<td class="r data">19</td>
<td class="data">Young popn based cohort free of medication + prospective data to address associations of amino acids in the early stage of pathogenesis of insulin resistance XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Insulin secretion =&gt; may potentially confound the reported associations with HOMA-IR =&gt; our study =&gt; circulating amino acid concns =&gt; in fasting state =&gt; associated primarily with insulin sensitivity rather than insulin secretion (13, 14). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Despite the prospective associations with HOMA-IR =&gt; the findings do not imply that the amino acids are mechanistically involved in the pathogenesis XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Several physiological and animal studies have suggested =&gt; direct promotion of insulin resistance by BCAAs (8, 27, 28).; however =&gt; genetic evidence =&gt; not provided support of  BCAAs in the pathogenesis (12). It is plausible =&gt; prospective associations with insulin resistance =&gt; occur as a result of indirect effects rather than being caused by altered amino acid levels. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Use of HOMA-IR as a surrogate of insulin resistance. However =&gt; fasting measure are adequate surrogates of insulin resistance =&gt; assessed by clamp test in the Finnish popn (35) XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The absence of insulin secretion assessment =&gt; limits correction of the prediction models =&gt; to establish independent prospective association with insulin resistance. But previously shown =&gt; fasting amino acid concns are primarily associated with insulin sensitivity rather than insulin secretion (13, 14) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX No established definition of what constitutes clinically significant insulin resistance =&gt; in particular for the young age group studied =&gt; however =&gt; similar results were obtained using alternative definitions to signify the highest extent of insulin resistance XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Due to the apparently healthy status of the young study popn =&gt; statistical power was inadequate to assess the 6-year risk of T2D XXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The results suggest =&gt; altered BCAA + AAA metabolism precedes development of insulin resistance already in early adulthood =&gt; prior to occurence of impaired fasting glucose + this could partly explain how these amino acids are linked with the risk of future T2D XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">Whether BCAAs + AAAs  =&gt; involved in development insulin resistance in a functional manner =&gt; remains to be established XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However =&gt; molecular underpinnings still to be determined + our findings highlight attention to sex differences in the role of amino acids in the pathogenesis =&gt; insulin resistance. Early identification of individuals at high risk for diabetes is of importance for prevention (33) XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  The clinical utility =&gt; amino acid profiling =&gt; for prediction of incident diabetes in older populations remains to be determined.</td>
</tr>
<tr>
<td class="r data">20</td>
<td class="data">The primary strength of this study is that, to our knowledge, we were among the first to adopt a targeted metabolomic approach at population level and included a large sample from three independent, well-described study populations. Furthermore, our targeted metabolomic platform covered a wide variety of metabolites with known identity and quantitative measurements. Because we used a prospective design with consecutive follow-up, we were able to investigate time-dependent exposure disease associations.</td>
<td class="data">The study, however, had several limitations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, because we used independent study populations, the conditions of biosample collection, storage, and preparation were not necessarily the same, which may be a source of variation. In the KORA and TüF studies, fasting blood samples were collected from all participants, whereas in EPIC-Potsdam only a small proportion of participants provided fasting blood samples. Nevertheless, we did not observe an effect modification of fasting status on the association between metabolite factors and T2D risk, and we could reproduce very similar metabolite factors comparing fasting to non-fasting samples. Furthermore, the metabolomic analyses were based on serum samples in the EPIC-Potsdam and KORA studies but on plasma samples in the TüF study. As previously reported (56), the correlation between these serum and plasma metabolites was high; however, the absolute metabolite concentrations were higher in serum, which could lead to systematic changes. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, the analytical method detected most of the metabolites with high specificity; however, it may not have detected all possible interferences among metabolites. Of the metabolites that we identified, diacylphosphatidylcholine C38:3 and sphingomyelin C16:1 may be interfering compounds for sphingomyelin C24:1 and diacyl-phosphatidylcholine C30:2, respectively. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, we only had a limited number of incident T2D cases available from KORA. We may not have had sufficient statistical power, and the replication results have to be interpreted with caution. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fourth, there is a chance that reverse causation may explain the results, implying that overt diabetic conditions that were undiagnosed may have caused these metabolite changes. When we accounted for this issue, the results remained robust. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, because this was an observational study, we cannot prove causality but only show associations. However, the identified metabolites were also correlated to established T2D biomarkers as well as to measures of insulin sensitivity and secretion in a different population, which underlines the biological plausibility of the results. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
<td class="data">The metabolites could also serve as markers for specific metabolic pathways that are deranged and, thereby, allow the implementation of individualized preventive and therapeutic strategies. However, future investigations are warranted to calculate in detail the individual risks and to better understand the metabolic effects of these biomarkers and their biological mechanisms. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Beyond the classic pathways, these candidates point toward a novel role of phospholipid and lipoprotein metabolism in T2D pathophysiology. Future studies should further elucidate the biological mechanisms. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
</tbody>
</table>
</div>
</div>
</body>
</html>
